U-PLEX®

NHP IL-13



www.mesoscale.com®

Ordering Information

MSD Customer Service
Phone: 1-240-314-2795
: 1-301-990-2776
Email: CustomerService@mesoscale.com

Scientific Support

Phone: 1-240-314-2798
Email: ScientificSupport@mesoscale.com

Company Address

MESO SCALE DISCOVERY®
A division of
Meso Scale Diagnostics, LLC.
1601 Research Boulevard
Rockville, MD 20850-3173 USA

Product Options	Catalog Number	Description
Multiplex	K15068M, K25068M	U-PLEX Biomarker Group 1 (NHP)
Singleplex	K156UBK-1/-2/-4	U-PLEX NHP IL-13 Assay with SECTOR™ plates
	K156UBK-21/-22/-24	U-PLEX NHP IL-13 Assay with QuickPlex® plates
	K256UBK-2/-4	U-PLEX NHP IL-13 Assay with 384-well plates
Antibody Set	B26UB-2	U-PLEX Human IL-13 Antibody Set (1 plate size)
Assay Protocol	U-PLEX Product Inserts are available at www.mesoscale.com	

The U-PLEX® platform was designed to provide ultimate flexibility for detection of biomarkers in a wide variety of sample types. This datasheet provides the representative performance of the U-PLEX NHP IL-13 Assay tested on U-PLEX 96-well SECTOR plates run as a multiplex. The data do not represent the product specifications. Under your experimental conditions, the assay may perform differently from the representative data. U-PLEX assays are offered in either singleplex or multiplex; both are available in 96- or 384-well plates. See a U-PLEX product insert for instrument compatibility.

Representative Calibration Curve and Sensitivity



Assay	Median LLOD (pg/mL)	LLOD Range (pg/mL)
IL-13	1.2	0.82—1.4

The Calibrator curve was fitted with a 4-parameter logistic model with a $1/Y^2$ weighting. The lower limit of detection (LLOD) is a calculated concentration corresponding to 2.5X the standard deviations above the background (zero Calibrator).

Precision

	Control	Average Conc. (pg/mL)	Average Intra-run Conc. %CV	Inter-run Conc. %CV
IL-13	High	1,133	2.9	7.5
	Mid	86	4.5	15.9
	Low	7.4	4.6	23.3

Controls were made by spiking Calibrator into assay diluent at 3 levels within the quantitative range of the assay. Average intra-run concentration %CV is the average %CV of the control replicates within an individual run. Inter-run concentration %CV is the variability of controls across multiple runs.

Spike Recovery

		Serum (N=5)		Plasma (N=5)		Cell Culture Media (N=5)	
	Spike Level	Average % Recovery	% Recovery Range	Average % Recovery	% Recovery Range	Average % Recovery	% Recovery Range
Cynomolgus Monkey	High	103	87-116	118	105-125	132	125-142
	Mid	97	84-105	104	88-110	114	95-129
	Low	88	74-95	94	86-98	138	127-147
Rhesus Monkey	High	123	111-127	115	103-120	132	125-142
	Mid	128	119-132	115	102-119	114	95-129
	Low	139	126-147	113	102-127	138	127-147

Normal serum, EDTA plasma, and cell culture media were spiked with Calibrator at 3 levels. Undiluted samples were tested to determine the expected concentration of the analyte. Samples may benefit from additional dilution with assay diluent to reduce matrix effects.

% Recovery = (measured concentration / expected concentration) x 100

Tested Samples

	Sample Type	Serum (N=10)	Plasma (N=10)	Stimulated PBMC Sample
Cynomolgus Monkey	Median (pg/mL)	NA	NA	12
	Range (pg/mL)	NA	NA	4.6-17
	% Detected	0	0	100
Rhesus Monkey	Median (pg/mL)	ND	ND	8.2
	Range (pg/mL)	ND-14	ND-9.7	ND-10
	% Detected	18	9.1	80

Normal serum and plasma samples were diluted 2-fold prior to the assay. ND = not detected (<LLOD); NA = not applicable due to 0% detected

Dilution Linearity

	Serum (N=5)			Plasma (N=5)			Cell Culture Media (N=5)		
	Fold Dilution	Average % Recovery	% Recovery Range	Fold Dilution	Average % Recovery	% Recovery Range	Fold Dilution	Average % Recovery	% Recovery Range
Cynomolgus Monkey	2	84	82-85	2	87	84-90	2	91	88-95
	4	72	69-76	4	75	68-78	4	84	81-89
	8	70	65-77	8	71	64-76	8	88	86-94
Rhesus Monkey	2	87	81-92	2	83	80-86	2	91	88-95
	4	73	68-77	4	67	63-70	4	84	81-89
	8	70	68-74	8	66	61-69	8	88	86-94

Normal serum, EDTA plasma, and cell culture media were spiked with Calibrator and tested at different dilutions. Undiluted samples were tested to determine the expected concentration of the analyte. Samples may benefit from additional dilution with assay diluent to reduce matrix effects.

% Recovery = (measured concentration / expected concentration) x 100

Specificity

To assess specificity, the IL-13 Antibody Set was tested individually against a larger panel of recombinant human analytes for nonspecific binding (CTACK, Eotaxin, Eotaxin-2, Eotaxin-3, ENA-78, FLT3L, Fractalkine, G-CSF, GM-CSF, GRO-α, I-309, IFN-α2a, IFN-γ, IL-1α, IL-1β, IL-1RA, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12/IL-23p40, IL-12p70, IL-13, IL-15, IL-16, IL-17A, IL-17A/F, IL-17B, IL-17C, IL-17D, IL-17F, IL-18, IL-22, IL-23, IP-10, I–TAC, MCP-1, MCP-2, MCP-3, MCP-4, M-CSF, MDC, MIF, MIP-1α, MIP-1β, MIP-3α, MIP-3β, MIP-5, SDF-1α, TARC, TNF-α, TNF-β, TPO, TRAIL, VEGF-A, and YKL-40). Nonspecific binding was less than 0.5%.

% Nonspecificity = (nonspecific signal / specific signal) x 100

Diluent Compatibility

Diluents 57 and 3 are provided with this assay. MSD offers a range of assay and antibody diluents for separate purchase. Depending on your assay needs, other diluents may be tested.

Assay Components

Calibrator: IL-13 is included in Calibrator 1. The full-length recombinant protein is expressed in *E. coli*.
Antibodies: The U-PLEX NHP IL-13 Assay uses a rat monoclonal antibody for capture and a mouse monoclonal antibody for detection.
Assay generation: B

Note: This datasheet contains representative assay performance data. In custom multiplex formats, the assay may perform differently than the representative data shown.